FDA Cancels Levothyroxine Product Stability Testing
This article was originally published in The Pink Sheet Daily
The agency says it does not plan to re-advertise for bids in the near term.
You may also be interested in...
Some manufacturers have been unable to demonstrate that their products have a two-year shelf life, the agency said.
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.
Agreements expand the firm’s position in the COPD space, while also entering obesity, diabetes and metabolic syndrome space.